Cargando…

Essential Medicines Are More Available than Other Medicines around the Globe

BACKGROUND: The World Health Organization (WHO) promotes the development of national Essential Medicines Lists (EMLs) in order to improve the availability and use of medicines considered essential within health care systems. However, despite over 3 decades of international efforts, studies show an i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bazargani, Yaser T., Ewen, Margaret, de Boer, Anthonius, Leufkens, Hubert G. M., Mantel-Teeuwisse, Aukje K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922716/ https://www.ncbi.nlm.nih.gov/pubmed/24533058 http://dx.doi.org/10.1371/journal.pone.0087576

Ejemplares similares

Selection of Essential Medicines for Diabetes in Low and Middle Income Countries: A Survey of 32 National Essential Medicines Lists
por: Bazargani, Yaser T., et al.
Publicado: (2014)

Essential medicines for breast cancer in low and middle income countries
por: Bazargani, Y. T., et al.
Publicado: (2015)

Selection of essential medicines for the prevention and treatment of cardiovascular diseases in low and middle income countries
por: Bazargani, Y. T., et al.
Publicado: (2018)

National medicines policies – a review of the evolution and development processes
por: Hoebert, Joëlle M, et al.
Publicado: (2013)

Medicine shortages: impact behind numbers
por: Postma, Doerine J., et al.
Publicado: (2023)

Availability, prices and affordability of UN Commission’s lifesaving medicines for reproductive and maternal health in Uganda
por: Kibira, Denis, et al.
Publicado: (2017)

Impact of medicine shortages on patients - a framework and application in the Netherlands
por: Postma, Doerine J., et al.
Publicado: (2022)

Impact of External Price Referencing on Medicine Prices – A Price Comparison Among 14 European Countries
por: Leopold, Christine, et al.
Publicado: (2012)

Sustainable Development Goal indicator for measuring availability and affordability of medicines for children: a proof-of-concept study
por: Joosse, Iris R, et al.
Publicado: (2023)

Five-year trends in treatment changes in an adult cohort of HIV/AIDS patients in Ghana: a retrospective cohort study
por: Ankrah, Daniel N. A., et al.
Publicado: (2017)

Decision Making Under Uncertainty: Comparing Regulatory and Health Technology Assessment Reviews of Medicines in the United States and Europe
por: Vreman, Rick A., et al.
Publicado: (2020)

Effect of the economic recession on pharmaceutical policy and medicine sales in eight European countries
por: Leopold, Christine, et al.
Publicado: (2014)

Access to oxytocin and misoprostol for management of postpartum haemorrhage in Kenya, Uganda and Zambia: a cross-sectional assessment of availability, prices and affordability
por: Kibira, Denis, et al.
Publicado: (2021)

Impact of regulatory requirements on medicine registration in African countries – perceptions and experiences of pharmaceutical companies in South Africa
por: Narsai, Kirti, et al.
Publicado: (2012)

Linking market authorizations of medicines with disease burden in South Africa
por: Narsai, K., et al.
Publicado: (2021)

Price changes of antibiotics and perceived substitutes in the context of OTC policy changes in Mexico and Brazil
por: Santa-Ana-Tellez, Yared, et al.
Publicado: (2015)

Cardiac Rehabilitation Availability and Density around the Globe()
por: Turk-Adawi, Karam, et al.
Publicado: (2019)

Longitudinal study of Good Pharmacy Practice roles covered at the annual world pharmacy congresses 2003–2019
por: Kusynová, Zuzana, et al.
Publicado: (2022)

Adverse events and patients’ perceived health-related quality of life at the end of multidrug-resistant tuberculosis treatment in Namibia
por: Sagwa, Evans L, et al.
Publicado: (2016)

Application of Managed Entry Agreements for Innovative Therapies in Different Settings and Combinations: A Feasibility Analysis
por: A Vreman, Rick, et al.
Publicado: (2020)

Trends in access to anti‐malarial treatment in the formal private sector in Uganda: an assessment of availability and affordability of first‐line anti‐malarials and diagnostics between 2007 and 2018
por: Kibira, Denis, et al.
Publicado: (2021)

Pre‐approval and post‐approval availability of evidence and clinical benefit of conditionally approved cancer drugs in Europe: A comparison with standard approved cancer drugs
por: Bloem, Lourens T., et al.
Publicado: (2022)

Missing data on accessibility of children’s medicines
por: Joosse, Iris R, et al.
Publicado: (2022)

Associations between uncertainties identified by the European Medicines Agency and national decision making on reimbursement by HTA agencies
por: Bloem, Lourens T., et al.
Publicado: (2021)

Regulatory scientific advice in drug development: does company size make a difference?
por: Putzeist, Michelle, et al.
Publicado: (2010)

Impact of Over-the-Counter Restrictions on Antibiotic Consumption in Brazil and Mexico
por: Santa-Ana-Tellez, Yared, et al.
Publicado: (2013)

Comparing amikacin and kanamycin-induced hearing loss in multidrug-resistant tuberculosis treatment under programmatic conditions in a Namibian retrospective cohort
por: Sagwa, Evans L., et al.
Publicado: (2015)

Marketing of medicines in primary care: An analysis of direct marketing mailings and advertisements
por: Dankers, Marloes, et al.
Publicado: (2023)

Addiction medicine in modern contexts: hot topics from around the globe
por: Elkholy, Hussien
Publicado: (2022)

Adverse events and adherence to HIV post-exposure prophylaxis: a cohort study at the Korle-Bu Teaching Hospital in Accra, Ghana
por: Tetteh, Raymond A., et al.
Publicado: (2015)

Association Between the Occurrence of Adverse Drug Events and Modification of First-Line Highly Active Antiretroviral Therapy in Ghanaian HIV Patients
por: Tetteh, Raymond A., et al.
Publicado: (2016)

Tenofovir-associated renal toxicity in a cohort of HIV infected patients in Ghana
por: Nartey, Edmund T., et al.
Publicado: (2019)

Use of Dipeptidyl Peptidase-4 Inhibitors and the Reporting of Infections: A Disproportionality Analysis in the World Health Organization VigiBase
por: Willemen, Marjolein J., et al.
Publicado: (2011)

The Application and Implications of Novel Deterministic Sensitivity Analysis Methods
por: Vreman, Rick A., et al.
Publicado: (2020)

Post‐marketing dosing changes in the label of biologicals
por: Minnema, Lotte A., et al.
Publicado: (2019)

Donor Commitments and Disbursements for Sexual and Reproductive Health Aid in Kenya, Tanzania, Uganda and Zambia
por: Kibira, Denis, et al.
Publicado: (2021)

Survey of Fertility Preservation Options Available to Patients With Cancer Around the Globe
por: Rashedi, Alexandra S., et al.
Publicado: (2020)

The role of Periodic Safety Update Reports in the safety management of biopharmaceuticals
por: Ebbers, Hans C., et al.
Publicado: (2012)

Drug development for exceptionally rare metabolic diseases: challenging but not impossible
por: Putzeist, Michelle, et al.
Publicado: (2013)

Drug Shortages From the Perspectives of Authorities and Pharmacy Practice in the Netherlands: An Observational Study
por: Postma, Doerine J., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_b7cpcepb7o20qk72o0khofolkj